It is hoped the survey will capture the experiences vets have had reporting ADRs, as well as identifying barriers to the current process which could be used to improve the ease with which ADRs are reported in the future.
PhD student Heather Davies (pictured right), who is leading the research project, said: "The survey is an important opportunity to gain insights into the issues that vets face when dealing with ADRs.
"We want to make the process easier in order to improve the safety of veterinary medicines, and ultimately, we need the help of professionals on the front line in order to do that."
She added: "The survey is relatively short and can be completed anonymously.
"We’re really keen to gather as many of your experiences as possible so we’d like to encourage veterinary professionals to complete it."
The research is being carried out as part of a PhD project funded by the Veterinary Medicines Directorate (VMD) in collaboration with the Small Animal Veterinary Surveillance Network (SAVSNET), based at the university.
The survey is now open and you can take part here: https://liverpool.onlinesurveys.ac.uk/adrs-vet
Any questions about the survey can be addressed directly to the researchers: Heather Davies (PhD student): H.H.Davies@liverpool.ac.uk and/or Dr David Killick (Supervisor): David.Killick@liverpool.ac.uk.
The Cat Friendly Veterinary Professional course is aimed at veterinary surgeons and nurses and covers all aspects of being cat friendly over six modules, including understanding where cats come from, their behaviours, stress free handling, how to be more cat friendly in practice and client communication.
The four-module Cat Friendly Veterinary Receptionist course is aimed at receptionists and includes everything a receptionist needs to know about cats and how to be cat friendly, including their role in making the practice cat friendly.
Both are 3 month online courses, with students working through the modules at their own pace. There is a short assessment at the end of each module and on successful completion of the course students will receive a certificate and badge.
Sarah Endersby, ISFM’s Veterinary Development Manager, said: "We are very excited to offer cat friendly training for individuals. The courses are suitable for all members of the practice team, and you do not have to work in an accredited Cat Friendly Clinic to study with us, meaning that there is something for everyone."
For more information and to sign up, visit https://icatcare.org/cat-friendly-courses.
Elle says she created the course she wished she had when she first qualified, one which offers provides practical tools and tailored support to build confidence, overcome self-doubt, and thrive in veterinary practice.
She said: “I remember what it felt like to step into practice as a newly qualified vet nurse—feeling unsure, overwhelmed, and constantly questioning whether I was good enough.
"That’s why I created this course - to give vet professionals the support and confidence they deserve.”
The Confidence Coaching CPD Course includes:
Elle says the course is ideal for both vets and vet nurses, in particular those struggling with confidence in their clinical skills, and professionals looking to progress in their careers.
The course costs £350, but as part of the launch, Elle is offering a 25% limited-time discount for those who sign up early using the code: PVN25.
https://thepositivevetnurse.com/cpd-course
Merial Animal Health has launched Allevinix, a flunixin-based non-steroidal anti-inflammatory (NSAID) pain killer for cattle, pigs and horses.
Victoria Hudson, Product Manager for Merial Animal Health said: "We have positioned Allevinix as the flexible flunixin that meets your needs, because it offers flexibility in every area.
"It is the only flunixin licensed for both intramuscular and intravenous administration in cattle and we know that this will be very welcome for many vets and farmers. It can be used across cattle, pigs and horses, and it is the first injectable NSAID to come in a durable, non-breakable bottle."
Merial says Allevinix is fast-acting against inflammation, pain and fever, reaching peak plasma levels approximately 30 minutes after injection. It is available in 100ml and 250ml PET bottles and joins Ketofen as part of a range of NSAIDs available from Merial. It can also be used in conjunction with Merial's antimicrobial treatment for calf pneumonia - Zactran.
Victoria added: "We believe that vets will find this is a useful and innovative addition to the range of options that they have in terms of NSAIDs. Allevinix has a number of advantages over other flunixin products currently on the market."
Andrea, who is also an EBVS Specialist in Small Animal Internal Medicine, is joining Paragon after returning from a spell in Australia. The transfer fee was not disclosed.
Andrea graduated from Bristol in 2011 and became a Specialist in 2017. She said: "I'm so pleased to be returning to my beautiful home county of Yorkshire and joining the brilliant team at Paragon.
"Internal medicine will be my key area and my main interests are infectious diseases and post graduate clinical teaching."
Andrea represented England youth at basketball between 2000 and 2002, starring in tournaments in Hungary and Italy, and her passion for sport is still high on her list of priorities.
She added: "Now I’m back home I’m looking to join a triathlon club and will attempt to master the ukulele, which I recently began playing."
Paragon managing director, Ian Monteith, said: "Andrea is the fifth high-calibre specialist addition we’ve made in the past six months which illustrates our dedication to delivering the highest level of care and treatment to our patients."
The new product contains a combination of Omega-3s, toxin binders and antioxidants which the company claims flush out toxins, aid blood flow to the kidneys and maintain kidney architecture.
Matthew Shaw, Managing Director of nutravet said: "We’re really excited to launch nutraren, it’s a product our team have been working on for some time to make sure we have developed the best renal product for vets to recommend to their clients.
"Using independent trial data, we’ve been able to develop a unique formulation for nutraren containing 100% natural ingredients to benefit a pet’s long-term kidney health."
Authorised veterinary practices can now order nutraren from nutravet.
For more information, contact nutravet on 0845 604 1688, visit: www.nutravet.co.uk or email: info@nutravet.co.uk.
Four new procedures have been added: cystostomy tube placement, endotracheal intubation, point-of-care ultrasound (POCUS), and wet-to-dry dressings.
The new video content, access to which is included with the printed book, has been designed as a ‘go to’ resource to reference prior to performing a procedure.
Nick Bexfield, one of the editors of the new edition, said: “We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed.”
Print copies are available through the BSAVA store, you can also access the digital version in the BSAVA Library.
Prices are £45.50 for BSAVA members; £70.00 for non-members.
Xperior Farm Health, one of the bidders for the government contracts to provide TB testing, has announced that it mounted a legal challenge to the procurement process, but has now withdrawn that challenge in the face of the 'aggressive' timeframe in which Defra demanded that it submit its case.
Xperior says it was made aware last month that all five Delivery Partner contracts would be awarded to members of the same veterinary group (XL Vets), which it felt would both compromise competition and make Defra overly reliant on one service provider.
In addition, Xperior said it believed the successful bids were unfeasibly low, which presents a potentially devastating threat to the viability of many rural vet practices and a seriously reduced quality of TB testing service to farmers.
Xperior says it initially notified a formal query to the Animal and Plant Health Agency (APHA - the executive agency of Defra responsible for awarding the contracts) during the pre-announcement consultation period, and believes other bidders may have done likewise. The query was dismissed, as a result of which the company issued legal proceedings.
Xperior's Veterinary Director, Phil Elkins said: "We are concerned that proposed payment rates for TB testing are considerably lower than those proposed by other bidders, and at a level which questions the viability of practices continuing to provide TB testing services to their clients.
"The consequence would be either unfairly low payment rates for official veterinarians (OVs) who conduct TB testing, or an influx of inexperienced vets, potentially from other countries, into low paid positions. The loss of TB testing income would also challenge the viability of some rural veterinary businesses and the relationships held with their clients.
"Either way, this is contrary to a key tenet in the pre-tender documentation that Delivery Partners are expected to maintain a flow of TB testing work and revenue to contribute to the capability of the veterinary profession in rural areas to support food security and the rural economy."
Meanwhile, an APHA spokesperson said they were limited in how much they could say before the formal announcement of the award, except that: “APHA is confident in the robustness of the procurement process and that the selected bidders are the best candidates to deliver this vital service in the most effective way.”
VetSurgeon.org understands that now the legal challenge has been dropped, an official announcement of the winner will likely be made within days. However, it also seems likely that the payment rates for OVs will remain confidential even after the announcement of the award, so it may be some time before the prospects for OVs become clear.
The survey was conducted by Mo Gannon & Associates, which asked 2,000 UK adults about their satisfaction with the service they and their animals received from veterinary surgeons, levels of trust in the profession, and whether the service provided by vets represents value for money.
32% of the respondents felt that veterinary surgeons represented excellent (8%) or good (24%) value for money. 38% thought that veterinary fees are fair. However, 29% thought that veterinary surgeons and their services provided poor (21%) or very poor (8%) value for money. The results were very similar to the last time the survey was conducted, in 2015.
Nevertheless, veterinary surgeons continue to enjoy very high levels of trust amongst the public. 94% said they either completely trust (34%) or generally trust (60%) vets. This put veterinary surgeons in third place amongst the most trusted professions, below opticians and pharmacists but above GPs and and dentists.
Satisfaction with the profession was also high. 80% said they were either very satisfied (39%) or satisfied (41%), putting vets in fourth place below opticians, pharmacists and dentists, but above general practitioners and accountants.
RCVS President Dr Niall Connell, pictured right (would you trust this man?) said: "These results clearly demonstrate that there is a great deal of good will towards the veterinary profession and the work they do in treating the nation’s animals and serving their communities. The basis of all good relationships is trust, and it is fantastic to see that our clients continue overwhelmingly to trust our knowledge and expertise and remain very happy with the service we provide them.
"The picture on value for money is clearly a bit more mixed, although clearly 70% of the respondents recognise that we at least charge fair fees in terms of our time and expertise. There is, of course, always more work that we can do in order to help the public understand veterinary costs and fees and promote the value of veterinary care, as demonstrated by last year’s joint Pets Need Vets social media campaign with BVA, in which we highlighted the benefits to pet owners of being registered with a vet."
The Disciplinary Committee had found Dr Schulze Allen guilty of four charges, namely that he had been convicted of the criminal offence of petty theft in the US which rendered him unfit to practise, and that on three subsequent occasions, twice to the RCVS and once to a notary in California, dishonestly represented that he had no criminal convictions.
Following the DC hearing, Dr Schulze Allen submitted an appeal to the Privy Council. The basis of his appeal revolved around whether, under Californian law, his conviction for petty theft was a conviction for a criminal offence or an infraction, and whether an infraction under US law was a criminal offence.
The RCVS had argued that while the theft is not a criminal felony in California, it would be considered so under English law.
However, the Board of the Privy Council which heard the appeal – comprising Lords Wilson, Carnwath and Lloyd-Jones, found the College had not proven beyond all reasonable doubt that Dr Schulze Allen was convicted of a criminal offence under Californian law. It therefore upheld his appeal against the DC’s finding that he had committed a criminal offence.
The Privy Council then considered Dr Schulze Allen’s appeal against the third and fourth of the charges against him - that he was dishonest in his representations to the College that he did not have a ‘criminal’ conviction and did not have a ‘criminal record’. The Privy Council found that, since the conviction for petty theft was an infraction, and was not a criminal offence and did not leave Dr Schulze Allen with a criminal record, then, strictly speaking, his representations to the RCVS were not false and so upheld his appeal against these two charges.
The Privy Council then considered Dr Schulze Allen’s appeal against the College’s second charge against him. This charge was that he had, in a written application for restoration to the Register, represented that he did not have any cautions, criminal convictions or "adverse findings". The College argued that he still had a responsibility to make a full and frank disclosure about his infraction, even if it did not meet the threshold of ‘criminal’ under Californian law.
The Board of the Privy Council said it had, on Dr Schulze Allen’s behalf, done its best to identify some argument that his conviction for a petty theft infraction did not amount to an "adverse finding", but failed. Rather, it found that "the conviction obviously amounted to an adverse finding."
The Board added that "there is no material by reference to which the Board [of the Privy Council] can depart from the [Disciplinary] Committee’s conclusion that, in answering “no” to that question, he knew that his answer was untrue. In other words, his denial was dishonest."
The Board therefore allowed the appeal against the DC’s conclusion on the first, third and fourth charges. But it dismissed the appeal against its conclusion on the second charge, namely that in that regard Dr Schulze Allen had been guilty of disgraceful conduct in a professional respect."
The Board then set aside the original sanction, that Dr Schulze Allen be removed from the Register, and tasked the Committee with identifying the appropriate sanction in relation to the second charge.
The Disciplinary Committee will now hold a further hearing to decide the sanction, at some time in the future. In the meantime Dr Schulze Allen remains on the Register of Veterinary Surgeons.
Paragon’s head of neurology, Massimo Mariscoli, says it will deliver better results for pets, improve the health and well-being of the surgeons using it, and improve the hospital’s ability to deal with complex spinal and brain surgeries.
Massimo, an EBVS and RCVS specialist in veterinary neurology said: “The operative microscope is an essential piece of equipment in the modern neurosurgical theatre.
“It delivers good magnification, good illumination without significant aberration or production of excessive heat and has a great internal stability which allows operational flexibility.
“There is also direct visual control of the instrumentation with the possibility to have magnifications up to 10 times with a good depth of field allowing a more natural three-dimensional vision.
“In addition, surgical microscopes allow multiple different magnifications while maintaining constant working distances which leads to excellent flexibility and versatility during surgical procedures.
“For example, low magnification is used during the drilling of the vertebral laminar or the skull and to ensure that the whole surgical field is clean before suturing the muscle layers.
“Higher magnification is used while dealing with delicate structures such as the spinal cord or brain.
“The higher magnification coupled with a good depth of view and stable three-dimensional vision also increases the security and safety when manipulating micro-surgical instruments near the nervous tissue.”
Massimo says that while the microscopes are not common in veterinary practices, he strongly believes they are an essential piece of equipment when dissecting close to the brain or spinal cord in small animals.
He also says that veterinary surgeons benefit from the technology: "The operative neurosurgical microscope is fixed to a self-levelling tripod, allowing multiple spatial configuration to ensure a perfect vision of the surgical field.
“This has a positive outcome on the health and well-being of the surgeons, with a 2013 study showing that, for nearly 85% of the time spent operating, surgeons have symmetrical, non-neutral, head-neck posture.”
For more information, visit www.paragonreferrals.co.uk.
Norbrook Laboratories has launched a long-acting cattle bolus which it says will reduce the risk of Milk Fever.
According to the company, Calcitrace D3 is the first and only long-acting bolus to offer slow and fast releasing calcium to provide sustained calcium levels for 48 to 72 hours. In addition, Calcitrace D3 provides Magnesium, Phosphate and Vitamin D3 making it the most comprehensive bolus available.
Calcitrace D3 is smooth gelatin coated bolus with a rounded tip designed for easier administration. Norbrook says it is smaller than other boluses making it less likely to cause trauma on the orpharynx during administration.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Milk Fever is a common metabolic disorder in dairy cattle which generally affects older, high producing cows and is caused by a rapid decrease in calcium concentrations in the blood just before calving. It is estimated that 3-10% of cows are affected by Milk Fever with a cost of more than £200 per incident so it is crucial that farmers and vets reduce the risk as effectively as possible.
"Norbrook's new Calcitrace D3 bolus which should be administered just before calving, provides higher calcium blood levels during the critical 12 - 48 hour post calving period and provides sustained increased levels for well beyond 48 hours. With the addition of Magnesium, Phosphate and Vitamin D3, Calcitrace D3 provides additional protection against Milk Fever."
Andrew Hillan MVB MRCVS, Director of Veterinary Sciences at Norbrook, led the development of Calcitrace D3. He said: "The launch of Calcitrace D3 is another illustration of the very high quality of technical expertise that exists within our research and development department and underlines Norbrook's commitment to developing high quality and innovative products. It comes from a strong and exciting pipeline of new products which we will bring to the market over the next couple of years."
Vets Now Ltd, the provider of out-of-hours emergency vet care has announced the acquisition of Salus Quality Partnerships (QP), a Health and Safety service provider to the veterinary profession in the UK.
Vets Now says this acquisition will extend the range of its services aimed at improving the quality of life within the profession and supporting practices to run more efficiently.
Vets Now currently runs 50 emergency clinics throughout the country including two referral hospitals in Scotland and the South West of England. In recent years Vets Now has extended its offering to the profession to include business services aimed at supporting vet practices. These services include Lifelearn (Client Education & Compliance), Staff Training Services, RCVS Practice Standards support and Practice Web services.
Salus QP, which has been running for over 18 years, offers veterinary practices information and services to help them comply with Health and Safety legislation and an anaesthetic monitoring service.
Richard Dixon, Founder of Vets Now said: "Our core purpose at Vets Now has always been to improve the lives of vets and pets, and the recent addition of Salus QP will help to do exactly that. The Salus QP team, led by Mark Enright and Alison Clark, have extensive knowledge in their field and crucially they fully understand the issues as they specifically apply to veterinary practices. With Salus QP our aim is to keep it simple and practical, helping practices fulfil their obligations without letting the Health and Safety tail wag the practice dog. I am very much looking forward to working with both Mark and Alison in the future as we take a fresh and common sense approach to Health and Safety in our profession."
Mark Enright said: "Salus QP and Vets Now both share a strong commitment to the veterinary profession and I truly believe that together we will be greater than the sum of our parts. I look forward to a future of innovations and benefits for all, and to continue to form quality partnerships within the veterinary profession."
"We would like to reassure vets, and through them dog owners, that we are constantly reviewing adverse event report data to ensure that the benefits of each UK licenced veterinary medicine product outweighs the risk posed by their potential side-effects.
There are a number of vaccines authorised in the UK containing either two (L2) or four (L4) strains of Leptospira. Based on the most recent periodic safety update report data received for each product, the incidence of adverse animal reactions for all L2 vaccine products combined is 0.015%; for L4 vaccine products this figure is 0.069%.
In other words, the VMD has received fewer than 2 adverse reactions for L2, and fewer than 7 for L4, for every 10,000 doses sold. This includes every suspected adverse event reported, even cases that were considered unclassifiable or were later found to be unrelated to the vaccine.
The overall incidence of suspected adverse reactions for both L2 and L4 vaccine products is therefore considered to be rare."
A 2012 RVC graduate, Daniella is the Principle Exotics Vet at ParkVet Hospital and is studying towards a certificate in Zoological Medicine. She said: "Despite their amazing work, the AWF struggles for funds to continue its vital work, so I have decided not only to be the first ever person to run the London Marathon for the AWF, but to run it in costume!
"Those who know me will be aware that running is not among my favourite activities, but I am stepping up to the challenge to raise much-needed funds for this fantastic charity that’s making a real, tangible difference to animals worldwide."
"Working full time in clinical practice, including being part of an out-of-hours rota, means training must be factored in with military precision: so far, some of my longer runs are planned for 4 am!
"I also entered the Hastings Half Marathon on 18 March, and my final training run prior to the big day is scheduled for when I will be in Queensland, Australia for my brother’s wedding.
"If I can manage 22 miles in those hot and humid conditions, the London Marathon should be a breeze!”
Chris Laurence. AWF Chair of Trustees, said: "I am delighted that Daniella has chosen to raise funds for AWF in what is arguably one of the biggest sporting events in the world. On behalf of the organisation, I’d like to thank her for her support and wish her all the best for the marathon."
To support Daniella’s fundraising, visit: https://uk.virginmoneygiving.com/DaniellaDosSantos
For updates on her training and to find out more about AWF, visit www.bva-awf.org.uk
Petplan Equine has announced the finalists for the fifth annual Petplan Equine Vet of the Year Award.
The winner of the award award, which is sponsored by Petplan Equine in association with Horse & Rider magazine, will be announced at the annual Animal Health Trust Equestrian Awards, being held at London's Lancaster Hotel on Thursday 1st November, 2012.
The finalists are:
Jess Hill BVM&S MRCVS Woodlands Veterinary Clinic, Cheltenham, Glos, EnglandJess, who qualified in 2003 at the University of Edinburgh Royal (Dick) School for Veterinary Studies, is described as simply "brilliant" for her outstanding calm, capable and kind approach to her work and the way in which she makes herself readily available to her clients. One nomination typifies all those received in praise of Jess' work: "She is incredibly knowledgeable and dedicated and nothing is too much trouble. She is great with horses - always quiet, kind and gentle. She works quickly and confidently, doesn't suggest unnecessary expensive procedures and is always cheerful and a pleasure to be with."
Keith Chandler BVMS Cert EP MRCVS, Kessock Equine Vets, Inverness, ScotlandKeith Chandler, a senior partner at Kessock Equine Vets received several nominations which credited not only him personally for his dedication, knowledge, pragmatic and caring approach but also his practice for its outstanding customer service. Upon receiving news of his nomination, Keith was swift to praise his team and explained: "This nomination reflects the exceptional team I have around me - together we strive to offer continuity, consistency and a minimum level of care to all our clients irrespective of which vet is in attendance."
Lee Paul, BSC BVM&S Cert EP MRCVS, Bushy Equine, Gwaelod-y-Garth, WalesNominations for Lee Paul, a specialist in internal and stud medicine who qualified at Edinburgh University's Royal Dick Veterinary School in 2002, unanimously praised his willingness to 'never give up' and to go beyond the call of duty. He is said to be highly dedicated and is praised for his willingness to always be available such as on the occasion when a horse he had been treating for a swelling in her throat presented complications during a weekend when he was not on duty. Despite this Lee, who had been contacted by the duty vet for background information, attended the call himself within an hour complete with the stethoscope he'd collected from the surgery en route and with his family in his car!
This year's judges were David Stickles, Head of Fund Raising at the Animal Health Trust, Alison Bridge, Editor of Horse & Rider magazine, Ben Mayes, President of the British Equine Veterinary Association (BEVA) and Gil Riley, 2009 Petplan Equine Vet of the Year.
Petplan says that the record number of high calibre nominations made it hard for the judges to choose three finalists. Isabella Von Mesterhazy, Head of Marketing for Petplan Equine said: "Anyone motivated to nominate their vet for this award must hold them in extremely high regard so once again we were very impressed by both the quality and quantity of nominations we received. It is heartwarming and inspiring to read the submissions that describe the outstanding contributions made by all the nominees in keeping owners happy and horses healthy. It has not been easy to select just three to go through to the final."
The winner will be posted on www.petplanequine.co.uk on Friday 2 of November.
The BVA is also calling on Government to tighten pet import rules.
The advice follows news about a positive Brucella canis test in a rescue dog imported from Belarus in March this year.
The woman fostering the dog was hospitalised after coming into close contact with it, in the UK’s first confirmed dog-to-human transmission.
The foster animal and four pet dogs who were exposed to the disease, three of whom also tested positive, all had to be euthanised.
Data released by the Government shows a steep rise in confirmed Brucella canis cases since the start of 2020, rising from just three before that year to 107 till July this year.
The dogs were all either imported, had returned from holiday overseas, or been bred with an imported dog.
BVA is asking veterinary teams to:
British Veterinary Association President Justine Shotton said: “This recent case of Brucella canis in a foster dog is extremely tragic and highlights why vets have long raised concerns over the real and serious risks of importing ‘Trojan’ rescue dogs with unknown health histories into the UK.
“We know there is an added public health risk too, including for veterinary teams who treat and handle these animals, from contact with an infected dog’s contaminated body tissues and fluids.
"BVA continues to call on the Government to take urgent action to introduce stricter pet import measures, including mandatory pre-import testing, so we can minimise the spread of Brucella canis and other emerging diseases.
"We are also calling for the strengthening of enforcement provisions and checks on dogs brought into the country through the commercial route."
The 2021 B. canis risk view and statement by Public Health England (now UK Health Security Agency) contains vital information and recommendations for veterinary professionals: here:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960013/20210210_Brucella_canis_statement.pdf
BVA’s recommendations on tightening pet travel legislation: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Companion_animals/BVA%20Position%20on%20Pet%20Travel%20Full.pdf
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
The service uses an Xstrahl 100 superficial radiotherapy system, a £150,000 piece of equipment installed by Paragon after it was used successfully in the USA by the hospital's medical and radiation oncology specialist, Dr Rodney Ayl.
Rodney (pictured right) says the new equipment will transform the way Paragon can treat skin cancers, dermatological disorders and some other common superficial conditions.
He said: “This is a very exciting development for us and our clients because Xstrahl systems have been used so successfully in human medicine for many years.
“This prompted us to explore adapting the SRT system for veterinary use in the UK and we hope to collaborate with Colorado State University, which has a similar unit, to develop protocols for pets.
“We believe this will be a significant advance in the treatment and care of animals and we’re delighted to be at the forefront of introducing this new service.
“It is the only one of its kind for pets in the UK and there are very few units like this anywhere in the veterinary industry, so it really is an important move forward.”
Xstrahl radiotherapy systems were originally designed for the treatment of skin cancer, dermatological disorders, certain types of benign disease and some palliative care in humans.
Rodney says that having adapted the SRT system for animals will transform their treatment and the logistics and cost of getting radiation therapy for superficial skin conditions.
He added: “Superficial radiotherapy is particularly useful for treating some types of skin cancer where it may be preferable to surgery as it can deliver excellent non-invasive outcomes with curative or palliative intent.
“The treatment is less stressful from the outset and, thanks to its mechanism of action, it is also pain-free.
“Its use of different size cones, directly over the lesion, minimises effects on healthy skin and the fast treatment means a large reduction in time and impact on the patient’s day-to-day life, while providing a highly-effective treatment.
“The machine’s flexibility also makes it particularly suited for treating multiple lesions that are difficult to access, such as the head and neck, without changing patient positioning.
“The Xstrahl 100 system will help us to respond to the growing demand for radiation treatment and we can treat these patients on an outpatient basis, helping us to reduce surgical and hospitalisation costs.
“The technology is a real winner. It is easy to use and helps us to deliver safe and effective radiotherapy to our animal patients.
“It provides a quicker, easier, cheaper and non-invasive alternative for superficial tumours, especially in geriatric patients where surgery is not always an option. We’re looking forward to seeing the positive results here at Paragon.”
The first is that the College will allow veterinary surgeons and nurses to carry over some of the CPD hours they have accrued in 2019 into 2020, to smoothen the transition to an annual hourly requirement.
Vets will be allowed to carry over 25 hours and VNs 10 hours of accumulated CPD from 2019 through to 2020.
This will apply once, in 2020 only, and is only applicable to vets and VNs who have been CPD-compliant from 2017 to 2019 and have a surplus number of hours to carry over.
Secondly, the College is going to allow vets and VNs to take a six-month 'CPD pause' for planned periods away from work, such as parental leave, and exceptional circumstances, such as serious ill health or unforeseen changes to family responsibilities, without the need to make up the hours when they return to work. This will reduce the burden on vets and VNs returning to work after a break.
RCVS Director of Education, Dr Linda Prescott-Clements said: "We hope that these changes to the CPD policy will support vets and VNs to make the transition to an annual hourly requirement.
"We received a sample of feedback from some members of the veterinary professions regarding the move to annual hourly CPD requirements and these additions have been introduced support members during this transition and to mitigate some of the concerns raised."
For more information about the CPD requirement for both vets and vet nurses, what activities might count as CPD, how to record your CPD and a series of frequently asked questions about CPD please visit our dedicated page: www.rcvs.org.uk/cpd.
The company says that practices transferring to its pet health plan portal will be able to take greater control of their pet health plans and benefit from a range of innovative services for the same cost. They include the VMD-approved Post2Pet home delivery service, a messaging system to advise clients on applying products, attending appointments or renewing prescriptions, reporting to give practice leaders the insights they need to drive plan performance, the ability for pet owners to sign up online rather than visit the practice, and 24/7 access to a marketing hub and the Premier Vet Alliance Learning Academy.
Premier Vet Alliance’s Business Development Director Andy Taylor said: "We are excited to be offering our high performing Premier Pet Care Plan to the many new practices joining us following our acquisition of Simplyhealth’s animal health business.
"We are working to make the transition seamless and believe that our new customers will be delighted at the expanded range of functionality our portal offers them, together with the reduced administrative burden. We will continue to invest in its development to ensure that all of our customers can be sure that their pet health plan offers the most powerful set of tools and services available to help them drive up the profitability of their practice, while offering gold standard care to their patients and peace of mind to their clients."
For more information, visit: https://premiervetalliance.com/uk/
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 3rd April 2019.
Matt Baker, presenter of The One Show and Countryfile, will be hosting the Ceva Animal Welfare Awards alongside the head judge, Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.
The award categories include:
Chris Laurence Vet of the Year – sponsored by Vet Record
Vet Nurse of the Year – sponsored by Agria Pet Insurance
Charity Team of the Year – sponsored by PDSA
Charitable Contribution of the Year – sponsored by Blue Cross
International Cat Care Welfare of the Year – sponsored by International Cat Care
Farmer of the Year – sponsored by R.A.B.I.
Farm Educator of the Year – sponsored by NADIS
Outstanding Contribution to Animal Welfare – sponsored by Your Dog and Your Cat magazines
To nominate someone for an award, visit www.cevawelfareawards.com. They can come from all walks of life and will be assessed on the evidence provided in the original nomination.
Entries must be in by Friday 25 January 2019.
Pergocoat contains pergolide, a long-acting dopamine receptor agonist.
It is available in 0.5mg (off-white) and 1mg (yellow) tablets for accurate dosing without the need to split tablets.
The tablets are film-coated to mask the bitter taste of pergolide and create a barrier between the horse owner and the active ingredient.
Available in two different pack sizes containing 60 or 160 tablets, Pergocoat tablets are packaged in double layered blister packs to help minimise the risk of accidental ingestion.
Rachel Addison BVM&S MRCVS, equine field support manager at Dechra said: “Pergocoat is available in two convenient tablet sizes to achieve an optimal treatment response.
"Horses can be monitored and reviewed every four to six weeks until stabilisation or improvement of clinical signs is observed.”
https://www.dechra.co.uk/products/horse/prescription/pergocoat#Pergocoat-0-5mg-60-film-coated-tablets-for-horses.
Zoetis has announced the launch of Simparica, a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age.
The company says the new product, which comes in the form of a tasty chewable tablet, acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month.
Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs.² It starts to kill fleas quickly within three hours³ and continues to kill fleas for at least 35 days², making it suitable as part of a treatment strategy for Flea Allergic Dermatitis.
The product also protects dogs against infestations with the most common ticks found to infest dogs in Europe2,4, including Dermacentor reticulatus, the species associated with the disease babesiosis, which has recently been reported in the UK. It’s also the only treatment for Ixodes hexagonus, one of the most prevalent ticks in the UK. The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and over 96% are killed within 24 hours.4
Zoetis says Simparica is also effective against Rhipicephalus sanguineus, and Sarcoptes scabiei, and that laboratory evidence shows efficacy for Demodex Canis and Otodectes Cynotis.
Zoetis believes that Simparica’s ability to provide continuous protection up to and beyond the monthly treatment period is very important for pet owners. Sixty three per cent of owners confess to giving flea and tick treatment later than when it was due, with the median being 5 days late.¹ Simparica gives vets and forgetful pet owners the peace of mind of extended duration of activity helping to minimise the potential risk of protection gaps.
Ned Flaxman, companion animal business unit director at Zoetis said: "With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and pet owner satisfaction. The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps vets and dog owners minimise the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for at least 35 days without losing efficacy — well beyond the monthly treatment period.
"With its rapid onset, robust duration of activity and very good safety profile, Simparica is the only oral isoxazoline indicated for four species of ticks in Europe including Ixodes hexagonus and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration."
For more information please speak to your account manager or contact customer support on 0854 300 8034.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses